IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections

Shionogi & Co., Ltd. presents new data at IDWeek 2025, demonstrating broad activity of Fetroja®/Fetcroja® (cefiderocol) across infection types and adult patient populations.